TCA
KRYS icon

Transcend Capital Advisors’s Krystal Biotech KRYS Stock Holding History

Transcend Capital Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.42M Buy
6,522
+4,011
+160% +$1.2M 0.16% 111
2026
Q1 		$649K Buy
2,511
+831
+49% +$221K 0.05% 332
2025
Q4 		$414K Hold
1,680
– – 0.03% 414
2025
Q3 		$297K Buy
+1,680
New +$251K 0.02% 538
2025
Q2 		– Sell
-1,383
Closed -$249K – 673
2025
Q1 		$249K Buy
1,383
+1
+0.1% +$168 0.02% 517
2024
Q4 		$217K Hold
1,382
– – 0.02% 523
2024
Q3 		$252K Buy
+1,382
New +$266K 0.02% 516

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Transcend Capital Advisors's KRYS Position: Q2 2026 in Review

Transcend Capital Advisors increased its Krystal Biotech (KRYS) stake by 160% in Q2 2026, buying an estimated $1.2M and bringing the position to 6,522 shares worth $2.42M. The position accounts for 0.16% of the portfolio, ranked #111.

Transcend Capital Advisors first reported a position in KRYS in Q3 2024 and has held it in 7 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Transcend Capital Advisors held 6,522 shares of Krystal Biotech worth $2.42M as of Q2 2026.
  • Transcend Capital Advisors bought 4,011 Krystal Biotech shares in Q2 2026, an estimated $1.2M.
  • Krystal Biotech made up 0.16% of Transcend Capital Advisors's portfolio in Q2 2026, its #111 holding.
  • Transcend Capital Advisors first reported a position in Krystal Biotech in Q3 2024 and has held it in 7 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Transcend Capital Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.